360 related articles for article (PubMed ID: 10576658)
1. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf IG; Finke S; Trojaneck B; Denkena A; Lefterova P; Schwella N; Heuft HG; Prange G; Korte M; Takeya M; Dorbic T; Neubauer A; Wittig B; Huhn D
Br J Cancer; 1999 Nov; 81(6):1009-16. PubMed ID: 10576658
[TBL] [Abstract][Full Text] [Related]
2. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer cells showing multidrug resistance and remaining cytotoxic activity to tumor cells after transfected with mdr1 cDNA.
Li HF; Yang YH; Shi YJ; Wang YQ; Zhu P
Chin Med J (Engl); 2004 Sep; 117(9):1348-52. PubMed ID: 15377427
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
[TBL] [Abstract][Full Text] [Related]
8. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
[TBL] [Abstract][Full Text] [Related]
9. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
10. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D
Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary assessment of immune reconstitution after autologous peripheral hematopoietic stem cell transplantation (AHSCT)].
Huang HQ; Cai QC; Shi YX; Lin XB; Wei J; Guo Y; Pan ZH
Ai Zheng; 2006 Aug; 25(8):1023-8. PubMed ID: 16965687
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
15. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
[TBL] [Abstract][Full Text] [Related]
17. [Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor].
Chen FX; Liu JQ; Zhang NZ; Gong XJ; Zhang GL; Xu YM; Zhou ZH; Wang T; Huang J
Ai Zheng; 2002 Jul; 21(7):797-801. PubMed ID: 12479111
[TBL] [Abstract][Full Text] [Related]
18. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.
Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS
Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283
[TBL] [Abstract][Full Text] [Related]
19. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]